Elite Pharmaceuticals, a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the commercial launch of generic methadone hydrochloride 5-mg and 10-mg tablets by Glenmark Pharmaceuticals, Elite's marketing alliance partner.
Methadone is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate. Methadone also can be used for detoxification treatment of opioid addiction — heroin or other morphine-like drugs — or maintenance treatment of opioid addiction in conjunction with appropriate social and medical services.
Glenmark will sell and distribute certain of Elite's generic products, including methadone, for which Elite will receive manufacturing and license fees.
There are currently four Elite products that Glenmark will sell. The equivalent brand and generic products have a market value of approximately $34 million, according to IQVIA data.
The launch of the additional products is expected to follow shortly.
"We are excited to begin our Glenmark Pharmaceuticals alliance with the launch of our newly approved generic methadone," Elite president and CEO Nasrat Hakim said.